Pelin Batur, MD Section of Women’s Health, Department of General Internal Medicine, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic
Holly L. Thacker, MD, FACP Departments of General Internal Medicine and Obstetrics and Gynecology; Head, Section of Women’s Health, Department of General Internal Medicine, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic; Clinical Associate Professor of Medicine, Penn State University, Hershey, PA
Halle C.F. Moore, MD Department of Hematology and Medical Oncology, Gault Women’s Health and Breast Pavilion, The Cleveland Clinic
Address: Pelin Batur, MD, Department of Internal Medicine, Gault Women’s Health and Breast Pavilion, A10, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail baturp@ccf.org
This paper discusses therapies that are not approved by the US Food and Drug Administration for some of the uses under discussion.
ABSTRACTAlthough the results of the Women's Health Initiative showed an increased risk of breast cancer in women taking hormone replacement therapy (HRT), the absolute risk is very low. We discuss limitations of the study, questions that remain, and how to discuss the study with women at average risk and high risk for breast cancer.
